Cognition, schizophrenia, and the atypical antipsychotic drugs
about
F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. I. In vitro receptor affinity and efficacy profileShould cognitive deficit be a diagnostic criterion for schizophrenia?Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical updateH1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.Placebo response in antipsychotic clinical trials: a meta-analysis.Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal modelsHippocampal shape and volume changes with antipsychotics in early stage psychotic illness.Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment.Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment.Potential enhancing effects of histamine H₁ agonism/H₃ antagonism on working memory assessed by performance and bold response in healthy volunteersBenefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function.The preclinical discovery and development of quetiapine for the treatment of mania and depression.Hippocampal place cell and inhibitory neuron activity in Disrupted-in-schizophrenia-1 mutant mice: implications for working memory deficits.Serotonergic hallucinogens differentially modify gamma and high frequency oscillations in the rat nucleus accumbens.Antipsychotic treatments; focus on lurasidone.Differential effects of typical and atypical antipsychotic drugs on striosome and matrix compartments of the striatum.The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.Hippocampal place cell and inhibitory neuron activity in disrupted-in-schizophrenia-1 mutant mice: implications for working memory deficits.
P2860
Q24564964-3742559F-F250-44EE-9547-7EFE7E434988Q24597744-57D5DB89-8641-439D-8457-31A71E79EA89Q26823735-8CD289E0-56D8-4A4C-A43F-DC7519A024D0Q33964839-C5CB07AC-8B0A-44D8-B8F1-60B6ED49CF02Q34169978-E954B485-512E-421F-95A2-4EED5487A69CQ34392600-11B067BA-A9E7-4AEA-970E-D05F7580D566Q34443837-1FFC75E8-DD1E-4AA5-9009-F96C86B2F513Q36099440-94E4AD08-495C-4D8D-A556-9FAF2EC1D61FQ36390750-67A195D9-FB9F-4AFA-B98D-74B92332902CQ36531343-C466EE8F-784B-45F8-8B31-4C3ECDCC7DAEQ36580637-717B2531-89DF-4F6F-8EF6-C3A02CE4D57EQ37151155-B3DC20F0-5DC6-4A17-ADB4-F1816EE60019Q38150484-590A9D73-820A-4C7E-AC12-4BD1754DE087Q39167761-2CBA4F61-0C22-4E40-9E2B-532FBA2934E2Q41773024-790A4762-0813-44BB-BF43-FDE165CA5ADBQ42175158-4AAE56A5-CAB1-40F7-ABC4-FFAC0D8A87C6Q42569343-2BDB1802-EBB6-4843-957A-B643EBED12CCQ43910663-1CBDB3EB-303B-4066-852B-466CFDB61203Q44407162-7C5ECE51-FC5D-4411-A75F-AED3530018E5Q47736845-70D26573-0C9B-4611-9473-7A56056BD20E
P2860
Cognition, schizophrenia, and the atypical antipsychotic drugs
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
1999年论文
@zh
1999年论文
@zh-cn
name
Cognition, schizophrenia, and the atypical antipsychotic drugs
@ast
Cognition, schizophrenia, and the atypical antipsychotic drugs
@en
type
label
Cognition, schizophrenia, and the atypical antipsychotic drugs
@ast
Cognition, schizophrenia, and the atypical antipsychotic drugs
@en
prefLabel
Cognition, schizophrenia, and the atypical antipsychotic drugs
@ast
Cognition, schizophrenia, and the atypical antipsychotic drugs
@en
P2093
P2860
P356
P1476
Cognition, schizophrenia, and the atypical antipsychotic drugs
@en
P2093
P2860
P304
13591-13593
P356
10.1073/PNAS.96.24.13591
P407
P577
1999-11-01T00:00:00Z